The goal of the BMMR2 challenge is to identify image-based markers derived from DW-MRI, alone or in combination with DCE-MRI, with improved performance over whole-tumor mean ADC for predicting pCR following neoadjuvant neoadjuvant chemotherapy (NAC) for invasive breast cancer. The challenge is being run by the Breast Imaging Research Program of UCSF through the NCI Quantitative Imaging Network (QIN). The challenge will open in June 2021 and run for four months.
...
- Pre-treatment (T0)
Prior to randomization patients received an MRI study including T2w, 4 b‑value DWI, and dynamic contrast-enhanced (DCE) acquisitions. - Early-treatment (T1)
After 3 weeks of regimen 1 treatment (Paclitaxel with or without an experimental agent). - Mid-treatment (T2)
Between Paclitaxel and Anthracycline (AC) treatment regimens.
...
- T2weighted sequence
- Diffusion-weighted imaging (DWI) sequence (b=0, 100, 600, 800 s/mm2, 3-direction)
- T1-weighted dynamic contrast enhanced (DCE) sequence (phase duration between 80 and 100sec; at least 8 minutes continuous post-injection acquisition)
Both original images and derived derived maps and segmentations from the DWI and DCE acquisitions are included in the collection
Links
Information and registration for the BMMR2 challenge: MedICI Challenges
...